Podcasts about Stock

Welcome! This week's guest is the hilarious Zach Zimmerman! Zach and Caleb talk moral dilemmas, parental expectations, good vs. evil, praise, so much more! Join our Substack for an exclusive post-episode chat with Zach and other bonus content! https://calebsaysthings.substack.com/ Follow Zach! @zzdoublezzFollow the show! @sooootruepod Follow Caleb! @calebsaysthings Produced by Chance Nichols @chanceisloudHead to https://www.squarespace.com/SOTRUE to save 10% off your first purchase of a website or domain using code SOTRUE.Stock up on sustainable cleaning products for yourself or to give a beautiful gift to your friends by going to https://www.Blueland.com/SOTRUE and get up to 30% during Blueland's holiday sale! Ready to quit for good? Go to https://www.quitwithjones.com/SOTRUE to start your personalized quitting journey and get $10 off with code SOTRUE.Use my code for 10% off your next SeatGeek order*: https://seatgeek.onelink.me/RrnK/SOTRUE10 Sponsored by SeatGeek. *Restrictions apply. Max $20 discount There's no replacement for human connection. Better with people. Better with Alma. Visit https://www.helloalma.com/SOTRUE to get started and schedule a free consultation today. About Headgum: Headgum is an LA & NY-based podcast network creating premium podcasts with the funniest, most engaging voices in comedy to achieve one goal: Making our audience and ourselves laugh. Listen to our shows at https://www.headgum.com. » SUBSCRIBE to Headgum: https://www.youtube.com/c/HeadGum?sub_confirmation=1 » FOLLOW us on Twitter: http://twitter.com/headgum » FOLLOW us on Instagram: https://instagram.com/headgum/ » FOLLOW us on TikTok: https://www.tiktok.com/@headgum So True is a Headgum podcast, created and hosted by Caleb Hearon. The show is produced by Chance Nichols with Associate Producer Allie Kahan. So True is engineered and edited by Nicole Lyons. Kaiti Moos is our VP of Content at Headgum. Thanks to Luke Rogers for our show art and Virginia Muller our social media manager.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

China's ascent tells two stories. One of power, precision, and industrial brilliance - the other of imbalance, aging, and constraint. In this episode, Alan Dunne and George Magnus trace the hidden geometry of that divide. They explore how a nation that builds for the future struggles to sustain its present: an economy split between advanced manufacturing and fading momentum, between the Party's control and the market's gravity. From local debt and demographic drag to rare-earth diplomacy and the politics of currency, Magnus sketches China not as a riddle to be solved, but as a system nearing the limits of its own design.-----50 YEARS OF TREND FOLLOWING BOOK AND BEHIND-THE-SCENES VIDEO FOR ACCREDITED INVESTORS - CLICK HERE-----Follow Niels on Twitter, LinkedIn, YouTube or via the TTU website.IT's TRUE ? – most CIO's read 50+ books each year – get your FREE copy of the Ultimate Guide to the Best Investment Books ever written here.And you can get a free copy of my latest book “Ten Reasons to Add Trend Following to Your Portfolio” here.Learn more about the Trend Barometer here.Send your questions to info@toptradersunplugged.comAnd please share this episode with a like-minded friend and leave an honest Rating & Review on iTunes or Spotify so more people can discover the podcast.Follow Alan on LinkedIn.Follow George on Twitter.Episode TimeStamps: 00:00 – Opening and disclaimer02:23 – George Magnus on career path and China focus06:56 – Data, distortions, and how to analyze China credibly11:37 – Two-track reality: advanced industry vs. a strained macro base16:56 – Why consumption rebalancing keeps failing22:29 – Stock-market boosts vs. household wealth effects25:45 – China's “QE by other means”: credit, banks, LGFVs27:40 – Who's levered? Local governments and off–balance sheet debt29:51 – Japan echoes and key differences33:23 – Trade frictions, rare-earth leverage, and U.S.–China...

Charles is joined by James Demmert, Main Street Research Chief Investment Officer to discuss how the market is priced for perfection and whether volatility is coming, the use of different valuation metrics rather than looking at historical earnings, and the legacy & future of Warren Buffett and Berkshire Hathaway. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Grow faster than 99% of Etsy shops

FURIA's first big trophy, Vitality and Falcons issues, MongolZ with controlez, Spirit looking cooked, and more takeaways from IEM Chengdu. In other topics: cadiaN's move to OG, tier-1 events getting canceled, and HLTV Hall of Fame drama.➡️ Follow us for updates: https://twitter.com/HLTVconfirmed

If you're charitably inclined and have investments in a taxable brokerage account, you might be leaving significant tax savings on the table. Most people automatically reach for their checkbook or credit card when making charitable donations, but there's a more tax-efficient strategy that could save you thousands of dollars over time.

Your daily dose of Texas history and Texas pride. Enjoy! Credit: Texas, On This Day. 500 Years of History, 2nd Edition by Gary C. Vliet. Stock media provided by Artmuns / Pond5 License v20180904

When is the right time to risk manage? What are a few readily available metrics you can gather when looking at a stock for the first time? Nate goes into his steps for the initial analysis of a publically traded company or stock. www.crosbyadvisory.com

Send us a textThis episode goes straight at the “noise” that stalls real progress: money blocks, old scripts, and the beliefs that keep you circling the same results. Eric shares a practical mindset workflow you can use to move from confusion to consistent action. Why? Because just telling someone they need to improve their money mindset is not enough--people need strategy. In this episode Eric covers:Spotting money blocks, including financial imposter syndromeYour money origin story and the scripts it createdA framework to open up to new beliefs and act on themHow to value and improve financial literacy so knowledge equals outcomesUsing mentors and coaches as leverage, not crutchesBuilding habits and routines that make saving, investing, and reviews automaticA weekly check-in that tracks one KPI and one next stepWhy it matters:Clarity beats noise. When you change the script, your choices change, then your numbers change. Support the showJOIN US ON PATREON: FINANCIAL TOOLS: AI powered Financial Coach Fin literacy course Stock course Accelerator SCALE YOUR MISSION BASED ORGANIZATION: https://www.productiveleaders.co/ FOLLOW US ON YOUR FAVORITE PLATFORM: MSG You Tube MSG LinkedIn MSG Facebook MSG Instagram MSG Tik Tok FOLLOW ERIC AND SCOTT: Eric: https://www.linkedin.com/in/ericmcloyd/ Scott: h...

Stock market update for November 12, 2025.

In this episode, reviews the YTD performance of Blackstone, KKR, and Apollo, & Carlyle Group.

So there's this moment in 2022 where Celia Hatch wakes up from a dream about chicken supplements called "Chicken Spice." She thinks it's ridiculous. Fast forward to today, and she's running a seven-figure business serving America's 13% of households with backyard chickens.The twist is it started as her teenage son's eighth-grade homework assignment. He made $500 selling herbs in craft bags, then quit. Ms. Hatch, a serial entrepreneur with 16 businesses behind her, picked it up and scaled Buff Clucks to seven figures in 18 months using Meta advertising, landing pages, and subscription bundling.This is a story about accidental entrepreneurship, the growing market of premium pet owners willing to double their feed costs, and why sometimes the best business ideas come to you in your sleep. Along the way, Celia reveals why their Shopify store is the "neglected child" of their operation, how a "sneeze warning" became genius marketing, and why she wishes she'd built a proper Shopify store from day one.SPONSORSSwym - Wishlists, Back in Stock alerts, & moregetswym.com/kurtCleverific - Smart order editing for Shopifycleverific.comZipify - Build high-converting sales funnelszipify.com/KURTLINKSBuff Clucks: https://www.buffclucks.com/Buff Clucks Instagram: https://www.instagram.com/buff_clucks/Funnelish (tool they use): https://funnelish.com/SEMrush: https://www.semrush.com/Ubersuggest: https://neilpatel.com/ubersuggest/WORK WITH KURTApply for Shopify Helpethercycle.com/applySee Our Resultsethercycle.com/workFree Newsletterkurtelster.comThe Unofficial Shopify Podcast is hosted by Kurt Elster and explores the stories behind successful Shopify stores. Get actionable insights, practical strategies, and proven tactics from entrepreneurs who've built thriving ecommerce businesses.

Asheesh Birla, CEO of Evernorth, interview. We discuss all the details of Evernorth's $1 billion XRP digital asset treasury.Topics: - Evernorth's mission as a XRP Treasury - Plans to go public on Nasdaq - How will XRP be purchased and will capital raise go beyond $1 billion - Preparing for a bear market - DATs vs ETFs Brought to you by 

Your daily dose of Texas history and Texas pride. Enjoy! Credit: Texas, On This Day. 500 Years of History, 2nd Edition by Gary C. Vliet. Stock media provided by Artmuns / Pond5 License v20180904

Fintech bank SoFi (SOFI) rolled out crypto trading to retail customers on Tuesday. The move sets the pace as the first of several national banks planning similar moves in the coming months. SoFi previously gave customers the ability to buy, sell, and hold crypto through its app, but it agreed to shutter that service two years ago to obtain approval for its national banking license.~This episode is sponsored by Tangem~Tangem ➜ https://bit.ly/TangemPBNUse Code: "PBN" for Additional Discounts!00:00 Intro00:10 Sponsor: Tangem00:30 BTC ETF demand stalls01:20 Mike Johnson: We should be open by tomorrow03:00 Unemployment piling04:30 Crypto bills05:00 McRib is back!05:30 SoFi CEO: First crypto bank launch08:20 Top 10 Banks09:00 Ripple bank next?11:00 Tom Lee: Retail is never wrong13:00 Uniswap switches fee incentive13:45 Solana ETFs outperforms15:00 Outro#Crypto #XRP #Bitcoin~First Crypto Bank Launches

XPeng Inc. (XPEV) joined other EV peers like Rivian (RIVN) in recent rallies by racing to a 3-year high. However, as George Tsilis explains, the company's leap into robotics is what's drawing investor attention. George talks about how the company is accelerating its positioning to compete with a tech giant like Tesla (TSLA).======== Schwab Network ========Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/ About Schwab Network - https://schwabnetwork.com/about

Using the tools I have, I can find stocks to add to a watch list, back test a strategy for that stock, get alerted to when to enter and exit executing trades and finding stocks to invest in. Here are the links to all the sales: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TRENDSPIDER - BLACK FRIDAY SALE - UP TO 70% OFF - up to 52 training sessions INCLUDED ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

On this IBKR Podcast episode, we explore how options market data reveals hidden signals that can help investors forecast stock movements with greater accuracy. Brian Tancock of Visual Sectors breaks down four predictive pillars, like asymmetric information and crowd wisdom, and explains how retail traders can use them to build smarter, market-neutral portfolios.

Stock market update for November 11, 2025.Follow us on Instagram ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@therundowndaily⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠This video is for informational purposes only and reflects the views of the host and guest, not Public Holdings or its subsidiaries. Mentions of assets are not recommendations. Investing involves risk, including loss. Past performance does not guarantee future results. For full disclosures, visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Public.com/disclosures⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.

In this episode, reviews the YTD performance of Blackstone, KKR, and Apollo, & Carlyle Group.

Episode 162 is on the scene and we are joined this week by the 11 time winner of the North South Shootout at Caraway Speedway Matt Hirschman. We ask Hirschman about a number of topics including the format of the race, how a scoring error could have changed the outcome of the event, why he chose to run the full time NASCAR Whelen Modified Tour this season this season, his thoughts on Gary Putnam becoming the new director of the tour and thoughts of his father being inducted in the New England Racers Hall of Fame as a non New England Resident.The winner of the Fall Brawl at Hickory Michael Bumgarner joins us to talk about the late race bump and run on Carson Kvapil, breaking the all time win record for a season at the track, his thoughts on jumping restarts and his full circle moment involving his father's race winning trophy that he had a hand in breaking.We discuss the Fall Brawl at Hickory, the Krush 250 at South Boston won by Kaden Honeycutt, restart violations and whether the restart zone should or should not be a thing, the All American 400 at Nashville, Jody turning 40, what joints and muscles hurt, the 10,000 to win Stock 4 event at Ararat and we pay tribute to Scott Phillips this week on DLN!

Nancy Pelosi's 17,000% stock returns have Americans asking if Congress is the real Wall Street. Patrick Bet-David breaks down how Pelosi turned $785K into $133M, insider trading loopholes in politics, and why both parties resist banning lawmakers from trading stocks.

Your daily dose of Texas history and Texas pride. Enjoy! Credit: Texas, On This Day. 500 Years of History, 2nd Edition by Gary C. Vliet. Stock media provided by Artmuns / Pond5 License v20180904

Reach out to Cody and Buhler to tell them what's up!Nobody's perfect...On today's episode of False Start, John Buhler (Lead Writer, FanSided) was not impressed by what he saw out of Indiana over the weekend.Cody Williams (Content Director, FanSided.com) tried to talk this rabid Dawg down, but to no avail...This is what happens when you schedule two podcasts within 12 hours of each other, and Buhler has to watch his Atlanta Falcons lose for the fourth time in a row.Regardless, the guys shared their new College Football Playoff brackets, who would be on the Heisman Trophy ballots, and what teams are College Football Playoff pretenders across the Power Four.If you wanted to hear all of the hottest takes on Garrett Nussmeier's fading NFL Draft stock, this is the show for you, buddy.All hail False Start!

Globalstar (GSAT) hit highs it hasn't seen since 2014 after B. Riley raised its price target on the satellite services company. George Tsilis centers on what the firm sees in the company's outlook and where the company stands compared to peers in Starlink and how Apple (AAPL) plays a pivotal role in its growth story.======== Schwab Network ========Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/ About Schwab Network - https://schwabnetwork.com/about

Stock market update for November 10, 2025.Follow us on Instagram ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@therundowndaily⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠This video is for informational purposes only and reflects the views of the host and guest, not Public Holdings or its subsidiaries. Mentions of assets are not recommendations. Investing involves risk, including loss. Past performance does not guarantee future results. For full disclosures, visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Public.com/disclosures⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.

Dr. Pedro Barata and Dr. Aditya Bagrodia discuss the evolving landscape of testicular cancer survivorship, the impact of treatment-related complications, and management strategies to optimize long-term outcomes and quality of life. TRANSCRIPT:  Dr. Pedro Barata: Hello and welcome to By the Book, a podcast series from ASCO that features engaging conversations between editors and authors of the ASCO Educational Book. I'm Dr. Pedro Barata. I'm a medical oncologist at University Hospitals Seidman Cancer Center and associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I'm also an associate editor of the ASCO Educational Book. We all know that testicular cancer is a rare but highly curable malignancy that mainly affects young men. Multimodal advances in therapy have resulted in excellent cancer specific survival, but testicular cancer survivors face significant long term treatment related toxicities which affect their quality of life and require surveillance and management. With that, I'm very happy today to be joined by Dr. Aditya Bagrodia, a urologic oncologist, professor, and the GU Disease Team lead at UC San Diego[KI1]  Health, and also the lead author of the recently published paper in the ASCO Educational Book titled, "Key Updates in Testicular Cancer: Optimizing Survivorship and Survival." And he's also the host of the world-renowned BackTable Urology Podcast. Dr. Bagrodia, I'm so happy that you're joining us today. Welcome. Dr. Aditya Bagrodia: Thanks, Pedro. Absolutely a pleasure to be here. Really appreciate the opportunity. Dr. Pedro Barata: Absolutely.  So, just to say that our full disclosures are available in the transcript of this episode.  Let's get things started. I'm really excited to talk about this. I'm biased, I do treat testicular cancer among other GU malignancies and so it's a really, really important topic that we face every day, right? Fortunately, for most of these patients, we're able to cure them. But it always comes up the question, "What now? You know, scans, management, cardio oncology, what survivorship programs we have in place? Are we addressing the different survivorship piece, psychology, fertility, et cetera?" So, we'll try to capture all of that today. Aditya, congrats again, you did a fantastic job putting together the insights and thoughts and what we know today about this important topic. And so, let's get focused specifically about what happens when patients get cured. So, many of us, in many centers, were fortunate enough to have these survivorship programs together, but I find that sometimes from talking to colleagues, they're not exactly the same thing and they don't mean the same thing to different people, to different institutions, right? So, first things first. What do you tell a patient perhaps when they ask you, "What can happen to me now that I'm done with treatment for testicular cancer?" Whether it's chemotherapy or just surgery or even radiation therapy? "So, what about the long term? What should I expect, Doctor, that might happen to me in the long run?" Dr. Aditya Bagrodia: Totally. I mean, I think that question's really front and center, Pedro, and really appreciate you all highlighting this topic. It was an absolute honor to work with true thought leaders and the survivorship bit of it is front and center, in my opinion. It's really the focus, you know, we, generally speaking should be able to cure these young men, but it's the 10, 15, 20 years down the way that they're going to largely contend with. The conversation really begins at diagnosis, pre-education. Fortunately, the bulk of patients that present are those with stage one disease, and even very basic things like before orchiectomy, talking about a prosthetic; we know that that can impact body image and self esteem, whether or not they decide to receive it or not. Actually, just being offered a prosthetic is important and this is something, you know, for any urologist, it's kind of critical. To discussing fertility elements to this, taking your time to examine the contralateral testicle, ask about fertility problems, issues, concerns, offer sperm banking, even in the context of a completely normal contralateral testicle, I think these things are quite important.  So if it's somebody with stage one disease, you know, without going too far down discussing adjuvant therapy and so forth, I will start the conversation with, "You know, the testes do largely two things. They make testosterone and they make sperm." By and large, patients are going to be able to have acceptable levels of testosterone, adequate sperm parameters to maintain kind of a normal gonadal state and to naturally conceive, should that be something they're interested in. However, there's still going to be, depending on what resource you look at, somewhere in the order of 10-30% that are going to have issues. Where I think for the stage one patients, it's really incumbent upon us is actually to not wait for them to discuss their concerns, particularly with testosterone, which many times can be a little bit vague, but to proactively ask about it every time. Libido, erectile quality, muscle mass maintenance, energy, fatigue. All of these are kind of associated symptoms of hypogonadism. But for a lot of kids 18-20 years old, it's going to be something insidious that they don't think about. So, for the stage one patients, it absolutely starts with gonadal function. If they are stage two getting surgery, I think the counseling really needs to center around a possibility for ejaculatory dysfunction. Now, for a chemotherapy-naive, nerve-sparing RPLND, generally these days we should be able to preserve ejaculatory function at high volume centers, but you still want to bring that up and again kind of touch base on thinking about sperm banking and so forth before the operation, scars, those are things I think worth talking about, small risk of ascites. Then, I think the intensity of potential long term adverse effects really ramps up when we're talking about systemic therapy, chemotherapy. And then there's of course some radiation therapy specific elements that come up. So, for the chemotherapy bits of it, I really think this is going to be something that can be a complete multi-system affected intervention. So, anxiety, depression, our group has actually shown using some population resources that even suicidality can be increased among patients that have been treated for germ cell tumor. You know, really from the top down, tinnitus, hearing changes, those are things that we need to ask about at every appointment. Neuropathy, sexual health, that we kind of talked about, including ED (erectile dysfunction), vertigo, dizziness, Raynaud's phenomenon, these are kind of more the symptoms that I think we need to inquire about every time. And what we do here and I think at a lot of survivorship programs is use kind of a battery of validated instruments, germ cell tumor specific, platinum treated patient specific. So we use a combination of EORTC questions and PROMIS questions, which actually serves as like a review of systems for the patient, also as a research element. We review that and then depending on what might be going on, we can dig into that further, get them over to colleagues in audiology or psychology, et cetera.  And then of course, screening for the hypertension, hyperlipidemia, metabolic syndrome with basically you or myself or somebody kind of like us serving, many times it's the role of the PCP, just making sure we're checking out, you know, CBC, CMP, et cetera, lipid parameters to screen for those kind of cardiac associated issues along with secondary malignancies. Dr. Pedro Barata: So that's super comprehensive and thorough. Thank you so much. Actually, I love how you break it down in a simple way. Two functions of the testes, produce testosterone and then, you know, the problem related to that is the hypogonadism, and then the second, as you mentioned, produce sperm and of course related to the fertility issues with that.  So, let's start with the first one that you mentioned. So, you do cite that in your paper, around 5-10% of men end up getting, developing hypogonadism, maybe clinical when they present with symptoms, maybe subclinical. So, I'm wondering, for our audience, what kind of recommendations we would give for addressing that or kind of thinking of that? How often are you ordering those tests? And then, when you're thinking about testosterone replacement therapy, is that something you do immediately or are there any guidelines into context that? How do you approach that? Dr. Aditya Bagrodia: So, just a bit more on digging into it even in terms of the questions to ask, you know, "Do you have any decrease in sexual drive? Any erectile dysfunction? Are your morning erections still taking place? Has the ejaculate volume changed? Physically, muscle mass, strength? Have you been putting on weight? Have you noticed increase in body fat?" And sometimes this is complicated because there's some anxiety that comes along with a cancer diagnosis when you're 20, 30 years old, multifactorial, hair loss, hot flashes, irritability. Sometimes they'll, you know, literally they'll say, "You know, my significant other or partners noticed that I'm really just a little bit labile." So I think, you know, there's the symptoms and then checking, usually kind of a gonadal panel, FSH, LH, free and total testosterone, sex hormone binding globulin, that's going to be typically pretty comprehensive. So if you've got symptoms plus some laboratory work, and ideally that pre-orchiectomy testosterone gives you some delta. If they started out at an 800, 900, now they're 400, that might be a big change for them. And then, when you talk about TRT (Testosterone Replacement Therapy) recommendations, you know, Pedro, yourself, myself, we're kind of lucky to be at academic centers and we've got men's health colleagues that are ultra experts, but at a high level, I would say that a lot of the TRT options center around fertility goals. Exogenous testosterone treats the low T, but it does suppress gonadal function, including spermatogenesis. So if that's not a priority, they can just get TRT. It should be done under the care of a urologist, a men's health, an endocrinologist, where we're checking liver chemistries and CBCs and a PSA and so forth. If they're interested in fertility preservation, then I would say engaging an endocrinologist, men's health expert is important. There's medications even like hCG, Clomid, which works centrally and stimulate the gonadal access. Niche scenarios where they might want standard TRT now, and then down the way, 5, 7 years, they're thinking about coming off of that for fertility purposes, I think that's really where you want to have an expert involved because there's quite a bit of nuance there in recovery of actual spermatogenesis and so forth.  To kind of summarize, you got to ask about it. Checking it is, is not overly complicated. We do a baseline pre-orchiectomy and at least once annually, you can tag it in with the tumor markers, so it's not an extra blood draw. And if they have symptoms of course, kind of developed, then we'll move that up in the evaluation. Dr. Pedro Barata: Got it. And you also touch base on the fertility angle, which is truly important. And I'm just curious, you know, a lot of times many of us might see one, two patients a year, right, and we forget these protocols and what we've got to do about that.  And so I'm interested to hear your thoughts about when you think about fertility, and how proactive you get. In other words, who do you refer for the fertility clinic, for a fertility preservation program? You know, do all cases despite getting through orchiectomy or just the cases that you're going to, you know you're going to seek chemotherapy at some point? What kind of selection or it depends on the chemo, like how do you do that assessment about the referral for preservation program that you might have available at UCSD? Dr. Aditya Bagrodia: Yeah, I mean I feel really fortunate to sit on the NCCN Testis Cancer Guidelines. It's in there that fertility counseling should be discussed prior to orchiectomy. So 100% bring it up. If there are risk factors, undescended testicles, previous history of fertility concerns, atrophic contralateral testicle, anything on the ultrasound like microlithiasis in the contralateral testicle, you kind of wanna get it there. And then again, there's kind of niche scenarios where you're really worried, maybe get a semen analysis and it doesn't look that good, arrange for the time of orchiectomy to have onco-testicular sperm extraction from the, quote unquote, "normal" testis parenchyma. You know, I think you have to be kind of prepared to go that route and really make sure you're doing this completely comprehensively.  So pre-orchiectomy all patients. Don't really push for it too hard if they've got a contralateral testicle, if they've had no issues having children. There's some cost associated with this, sperm banking still isn't kind of covered even in the context of men with cancer. If they've got risk factors, absolutely pre-orchiectomy. Pre-RPLND, even though the rates of ejaculatory dysfunction at a high-volume center should be low single digits, I'll still offer it. That'd be a real catastrophe if they were in that small proportion of patients and now they're going to be reliant on things like intrauterine insemination, where it becomes quite expensive.  Pre-chemo, everybody. That's basically a standard these days where it should be discussed and it's kind of amazing currently, even if you don't have an accessible men's health fertility clinic, there are actually companies, I have no vested interest, Fellow is one such company where you can actually create an account, receive a FedEx semen analysis and cryopreservation kit, send it back in, and all CLIA certified, it's based out of California. The gentleman that runs it, is a urologist and very, very bright guy who's done a lot of great stuff for testis cancer. So, even for patients that are kind of in extremis at the hospital that kind of need to get going like yesterday, we still discuss it. We've got some mechanisms in place to either have them take a semen analysis over to our Men's Health clinic or send it off to Fellow, which I think is pretty cool and that even extends to some of our younger adolescent patients where going to a clinic and providing a sample might be tricky.  So, I think bringing it up every stage, anytime there's an intervention that might be offered, orchiectomy, chemo, surgery, radiation, it's kind of incumbent on us to discuss it. Dr. Pedro Barata: Gotcha. That's super helpful. And you also touch base on another angle, which is the psychosocial angle around this. You mentioned suicidal rates, you mentioned anxiety, perhaps depression in some cases as well as chronic fatigue, not necessarily just because of the low testosterone that you can get, but also from a psychological perspective. I'm curious, what do the recommendations look like for that? Do these patients need to see a social worker or a psychologist, or do they need to answer a screening test every time they come to see us and then based on that, we kind of escalate, take the next steps according to that? Do they see a psychologist perhaps every so often? How should that be managed and addressed? Dr. Aditya Bagrodia: It's an excellent question and again, these can be rather insidious symptoms where if you don't really dig in and inquire, they can be glossed over. I mean, how easy to say, "Your markers look okay, your scans look okay. See you in six months," and keep it kind of brief. First off, I think bringing it up proactively and normalizing it, that, "This may be something that you experience. Many people do, you're not alone, there's nothing kind of wrong with you." I also think that this is an area where support groups can be incredibly useful. We host the Testicular Cancer Awareness Foundation support group here. They'll talk about chemo brain or just like a little bit of an adjustment disorder after their diagnosis. Support groups, I think are critical. As I mentioned, we have a survivorship program that's led by a combination of our med oncs, myself on the uro-onc side, as well as APPs, where we are systematically asking about essentially the whole litany of issues that may arise, including psychosocial, anxiety, depression, suicidality. And we've got a nice kind of fast path into our cancer center support services for these young men to meet with a psychologist. If that isn't going to be sufficient, they can actually see a psychiatrist to discuss medications and so forth. I do think that we've got to screen for these because, as anticipated from diagnosis, those first 2 years, we see a rise. But even 10, 15 years out, we note, compared to controls, that there is an increased level of anxiety, depression, suicidality that might not just take place at that initial acute period of diagnosis and treatment. Dr. Pedro Barata: Really well said. Super important.  So I guess if I were to put all these together, with these really amazing advances in technology, we all know AI, some of us might be more or less aware of biomarkers coming up, including microRNA for example, and others, like as I think of all these potential long term complications for these patients, look at the future, I guess, can we use this as a way to deescalate treatment where it's not really necessary, as a way to actually prevent some of these complications? Like, how do we see where we're heading? As we manage testicular cancer, let's say, within the next 5 or 10 years, do you think there's something coming up that's going to be different from what we're doing things today? Dr. Aditya Bagrodia: Totally. I mean, I think it's as exciting as a time as there's ever been, you know, maybe notwithstanding circa 1970s when platinum was discovered. So microRNAs, which you mentioned, you know, there's a new candidate biomarker, microRNA-371. We are super excited here at UCSD. We actually have it CLIA-certified available in our lab and are ordering these tests for patients kind of in their acute stage, you know, stage one and surveillance, stage two, post-RPLND, receiving chemotherapy. And essentially this is a universal germ cell tumor specific biomarker, except for teratoma, suffice it to say 90% sensitive and specific. And I think it's going to change the way that we diagnose and manage patients. You know, pre-orchiectomy, that's pretty straightforward. Post-orchiectomy, maybe we can really decrease the number of CT scans that are done. Maybe we can identify those patients that basically have occult disease where we can intervene early, either with RPLND or single cycle chemo. Post-RPLND, identify the patients who are at higher risk of relapse that may benefit from some adjuvant therapy. In the advanced setting, look at marker decline for patients in addition to standard tumor markers. Can we modulate their systemic therapy?  So, the international interest is largely on modifying things. There's really cool clinical trials that we have for stage one patients, that treatment would be prescribed based on a post-orchiectomy microRNA. I think the microRNAs are really exciting. Teratoma remains an outstanding question. I think this is where maybe ctDNA, perhaps some radiomics and advanced imaging processing and incorporating AI may allow us to safely avoid a lot of these post-chemo RPLNDs. And then identification using SNPs and so forth of who might be most susceptible to some of the cardiac toxicity, autotoxicity and personalizing things in that way as well. Dr. Pedro Barata: Super exciting, right, what's about to come? And I agree with you, I think it's going to change dramatically how we manage this disease.  This has been a pleasure sitting down with you. I guess before letting you go, anything else you'd like to add before we wrap it up? Dr. Aditya Bagrodia: Yeah, first off, again, just want to thank you and ASCO for the opportunity. And it's easy enough to, I think, approach a patient with the testicular germ cell tumor as, "This is an easy case. We're just going to do whatever we've done. Go to the guidelines that says do X, Y, or Z." But there's so much more nuance to it than that. Getting it done perfectly, I think, is mandatory. Whatever we do is an impact on them for the next 50, 60, 70 years of their life. And I found the germ cell tumor community, people are really passionate about it. If you're ever uncertain, there's experts throughout the country and internationally. Ask somebody before you do something that you can't undo. I think we owe it to them to get it perfect so that we can really maximize the survivorship and the survival like we've been talking about. Dr. Pedro Barata: Aditya, thanks for sharing your fantastic insights with us on this podcast. Dr. Aditya Bagrodia: All right, Pedro. Fantastic. Appreciate the opportunity. Dr. Pedro Barata: And also, thank you to our listeners for your time today. I actually encourage you to check out Dr. Bagrodia's article in the 2025 ASCO Educational Book. We'll post a link to the paper in the show notes. Remember, it's free access online, and you can actually download it as well as a PDF. You can also find on the website a wealth of other great papers from the ASCO Educational Book on key advances and novel approaches that are shaping modern oncology.  So with that, thank you everyone. Thank you, Aditya, one more time, for joining us. Thank you, have a good day. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:         Dr. Pedro Barata  @PBarataMD   Dr. Aditya Bagrodia @AdityaBagrodia Follow ASCO on social media:         @ASCO on X (formerly Twitter)         ASCO on Bluesky        ASCO on Facebook         ASCO on LinkedIn         Disclosures:      Dr. Pedro Barata:  Stock and Other Ownership Interests: Luminate Medical  Honoraria: UroToday  Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon  Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas  Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck   Dr. Aditya Bagrodia: Consulting or Advisory Role: Veracyte, Ferring  

www.TheMasonAndFriendsShow.com https://thejuunit.bandcamp.com/releases https://www.youtube.com/@SuperStationWJDL-TV5 A Ridiculous Fever Dream of Pro Wrestling Presented by J Dub https://www.glass-flo.com Great Pipes for Sure shortened episode, due to a technical snafu, predator, disney, glass room in the woods, mike watching movies, old, odd pregnancy, Ju's bad bunny, Betting Unit, no watch, Lisa Betting? Gambling Impact, Stock betting, yes or no bets, cartridge mess, digging around, pizza pieces, donut late excuse, the music of this episode@ https://open.spotify.com/playlist/52Cx3W2HQtVr6OzINDtgW3?si=ac93216d5d9d4a23 support the show@ www.patreon.com/MperfectEntertainment

Your daily dose of Texas history and Texas pride. Enjoy! Credit: Texas, On This Day. 500 Years of History, 2nd Edition by Gary C. Vliet. Stock media provided by Artmuns / Pond5 License v20180904

The oldest members of Generation X reach 60 this year. Yet most have much less than $300,000 saved for retirement, while also carrying more student loan and credit card debt than any other generation. Robert Brokamp discusses the challenges and solutions with Kerry Hannon, co-author of Retirement Bites: A Gen X Guide to Securing Your Financial Future. Also in this episode: -Stock market valuations are high, but there are reasons to believe the bull market can continue-Unused 529 college savings money can be transferred to a Roth IRA and not be subject to federal taxes (if done right). But what about state taxes?-Recent reports from Vanguard and J.P. Morgan Asset Management have sobering projections for U.S. stocks over the next 10 to 15 years-Over the holidays, eat, drink, be merry, and discuss estate planning with your family Host: Robert BrokampGuest: Kerry HannonEngineer: Bart Shannon Advertisements are sponsored content and provided for informational purposes only. The Motley Fool and its affiliates (collectively, "TMF") do not endorse, recommend, or verify the accuracy or completeness of the statements made within advertisements. TMF is not involved in the offer, sale, or solicitation of any securities advertised herein and makes no representations regarding the suitability, or risks associated with any investment opportunity presented. Investors should conduct their own due diligence and consult with legal, tax, and financial advisors before making any investment decisions. TMF assumes no responsibility for any losses or damages arising from this advertisement. We're committed to transparency: All personal opinions in advertisements from Fools are their own. The product advertised in this episode was loaned to TMF and was returned after a test period or the product advertised in this episode was purchased by TMF. Advertiser has paid for the sponsorship of this episode Learn more about your ad choices. Visit megaphone.fm/adchoices

Your daily dose of Texas history and Texas pride. Enjoy! Credit: Texas, On This Day. 500 Years of History, 2nd Edition by Gary C. Vliet. Stock media provided by Artmuns / Pond5 License v20180904

Chris Markowski discusses the importance of financial preparation and the need to address financial issues immediately. He emphasizes the significance of building an anti-fragile portfolio and understanding market realities, while also critiquing the role of big firms in financial losses. The conversation covers investment strategies, the psychology of investing, and the dangers of prioritizing social media image over financial stability.

À l'Antichambre, Luc Bellemare est en compagnie de Karell Emard, Norman Flynn et P.J. Stock pour parler des Canadiens.

In this episode, we explore Meta's ambitious $600 billion investment in AI infrastructure and the resulting 12% drop in their stock value. We delve into Mark Zuckerberg's strategy to stay competitive in the AI race and the challenges Meta faces in generating meaningful revenue from these investments.Our Skool Community: https://www.skool.com/aihustleGet the top 40+ AI Models for $20 at AI Box: ⁠⁠https://aibox.ai

Learn more about your ad choices. Visit megaphone.fm/adchoices

Kara and Scott discuss Democrats' Election Night victories, and what they mean for the 2026 midterms. Then, Palantir's stock takes a dive amid overvaluation and shorting concerns, and Tesla shareholders vote on Elon Musk's trillion-dollar pay package. Plus, Trump's tariffs face the Supreme Court, and the far right erupts in civil war over Tucker Carlson's interview with white nationalist Nick Fuentes. We're going on tour! Get tickets at pivottour.com Watch this episode on the ⁠⁠Pivot YouTube channel⁠⁠.Follow us on Instagram and Threads at ⁠⁠@pivotpodcastofficial⁠⁠.Follow us on Bluesky at ⁠⁠@pivotpod.bsky.social⁠⁠Follow us on TikTok at ⁠⁠@pivotpodcast⁠⁠.Send us your questions by calling us at 855-51-PIVOT, or email Pivot@voxmedia.com Learn more about your ad choices. Visit podcastchoices.com/adchoices

Another year, another trip through the five boroughs. We recap our experience during the New York City Marathon weekend, including an epic shakeout run with New Balance, the united front of our 4-hour pace group, and the full rundown of race day as we covered 26.2 from Staten Island to Central Park. Wide Foot Jarrett fills in for Thomas.SUPPORT OUR SPONSORS!MAURTENThe top two men and top three women at the New York City Marathon used Maurten to fuel their race efforts, including all three women finishing under the previous course record. We also used Maurten for our entire race, finishing strong without bonking. Stock up for your own fall races and save 15% off your order by using this link and code Believe15: https://bit.ly/BITR-MAURTENLMNTWe used LMNT before and during the New York City Marathon to keep our salt and electrolyte levels topped off. With 1,000 mg of sodium plus other key electrolytes, LMNT helps restore balance to your life after any hard effort. Order today and get an 8-count LMNT Sample Pack with any purchase, so don't miss out: http://drinklmnt.com/thedrop

Bass After Dark — inch for inch and pound for pound, the best show in fishing — is back for another lively, and LIVE, episode. Don't miss Ken Duke, Brian the Carpenter, and our three mystery panelists (spoiler alert: it's Dr. Michael T. Lardon, Jared Lintner, and Drew Gill) as we tackle the question: How do you improve your mental game?VOTE for Bass After Dark as the Best Bass Fishing Podcast!https://bestontour.net/awards/

RU367: NICK STOCK & NICK PEIM ON THE LACANIAN TEACHER: EDUCATION, PEDAGOGY & ENJOYMENT https://renderingunconscious.substack.com/p/ru367-nick-stock-and-nick-peim-on Rendering Unconscious episode 367. Rendering Unconscious welcomes Drs. Nick Stock and Nick Peim to the podcast! They're here to talk about their new book The Lacanian Teacher: Education, Pedagogy and Enjoyment (The Palgrave Lacan Series). https://amzn.to/47LBV8c In this episode, Nick Stock and Nick Peim delve into their Lacanian perspective on education. They discuss the fantasy of the English teacher's unique role, the pervasive myth of educational redemption, and the enjoyment derived from teaching despite its challenges. The discussion highlights the symbolic order of education, the impact of neoliberalism, and the ontological significance of the signifier. They explore the pleasure in teaching, the tragic ethic, and the hysterical mode of teaching, emphasizing the importance of the signifier and the teacher's subjective experience within the educational symbolic order. Listen to this previous episode with Nick Stock: RU253: NICHOLAS STOCK – “DOES THE TEACHER ENJOY? THINKING THROUGH EDUCATIONAL ENJOYMENT WITH LACAN” http://www.renderingunconscious.org/psychoanalysis/ru253-nicholas-stock-does-the-teacher-enjoy-thinking-through-educational-enjoyment-with-lacan/ The song at the end of this episode is "We will be (outside the box)" by Vanessa Sinclair and Pete Murphy from the album "The cutting up of love and language" available for free download/name your price at https://petemurphy.bandcamp.com Enjoy! Thank you for being a paid subscriber to Rendering Unconscious Podcast. It makes my work possible. If you are so far a free subscriber, thanks to you too. Please consider becoming a paid subscriber to gain access to all the material on the site, including new, future, and archival podcast episodes. It's so important to maintain independent spaces free from censorship and corporate influence. Thank You.

Your daily dose of Texas history and Texas pride. Enjoy! Credit: Texas, On This Day. 500 Years of History, 2nd Edition by Gary C. Vliet. Stock media provided by Artmuns / Pond5 License v20180904

Craig Warnimont thinks market analysts are competing to call the first domino that might take the market down instead of finding client opportunities. He gives his best-positioned sectors for 2026, as well as some stock-specific examples, like Applovin (APP), Palantir (PLTR), and Nvidia (NVDA). He focuses on how to use P/E numbers and revenue to find hidden gems.======== Schwab Network ========Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/ About Schwab Network - https://schwabnetwork.com/about

JFrog (FROG) shares hopped to a 4-year high after the software supplier after beating earnings and raising its 2025 outlook. Alex Coffey takes a closer look into the company's financials to explain whether JFrog can find its footing after the stock leapt 25% on Friday's session.======== Schwab Network ========Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/ About Schwab Network - https://schwabnetwork.com/about

On this episode of Chit Chat Stocks, we speak with Dave Ahern of the Investing For Beginners Podcast. We discuss how Nubank has come to dominate the online banking space in Latin America. We explore their innovative digital banking model, growth strategies in Brazil and Mexico, potential expansion into other Latin American markets, and the implications of applying for a U.S. banking license.(03:22) Understanding NuBank's Business Model(06:08) Growth Strategies in Brazil(10:30) Expansion Potential in Mexico(16:34) Future Expansion in Latin America(22:37) Why NuBank applied for a U.S. Banking License(25:47) Exploring Growth Beyond Financial Services(31:43) Management Insights: David Velez and His Leadership(36:56) Valuation and Growth ProjectionsVALUE SPOTLIGHT: https://einvestingforbeginners.com/value-spotlight-newsletter/*****************************************************JOIN OUR EMAIL NEWSLETTER AND CHAT COMMUNITY: ⁠https://chitchatstocks.substack.com/⁠ *********************************************************************Chit Chat Stocks is presented by Interactive Brokers. Get professional pricing, global access, and premier technology with the best brokerage for investors today: ⁠https://www.interactivebrokers.com/⁠ Interactive Brokers is a member of SIPC. *********************************************************************Fiscal.ai is building the future of financial data.With custom charts, AI-generated research reports, and endless analytical tools, you can get up to speed on any stock around the globe. All for a reasonable price. Use our LINK and get 15% off any premium plan: ⁠⁠https://fiscal.ai/chitchat⁠ *********************************************************************Portseido is your best portfolio tracking & reporting solution that helps you track all investments in one place. We personally use the software to track our portfolio returns across brokerage accounts. Get up to 40% off Nov. 26th - Dec. 1st with our link: https://portseido.com/?fpr=ryan63⁠ *********************************************************************Disclosure: Chit Chat Stocks hosts and guests are not financial advisors, and nothing they say on this show is formal advice or a recommendation.

From Wall Street to Main Street, the latest on the markets and what it means for your money. Updated regularly on weekdays, featuring CNBC expert analysis and sound from top business newsmakers. Anchored and reported by CNBC's Jessica Ettinger. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

Comments? Feedback@SellSellSell.online or Facebook *** Thankyou and Au Revoir Tyvek *** Cyberstalking: Partial Settlement *** Sneaky Change to Promoted Listings Charging *** There's No Such Thing as "Stock" Photos? *** Your Photos Stolen? What You Can Do

Send us a textInvest in pre-IPO stocks with AG Dillon & Co. Contact aaron.dillon@agdillon.com to learn more. Financial advisors only.00:00 - Intro00:07 - Tether $10B+ Profit Fuels $20B Buyback Ambition01:05 - Ripple $500M Raise at $40B Valuation Boosts Global Payment Push01:53 - Decagon Eyes $4-5B Valuation on 100x ARR Multiple02:38 - Crusoe Tender Implies $13B Valuation (+30%)03:20 - Google-Wiz $32B Deal (+39%) Clears DOJ04:09 - Armis $435M Pre-IPO Round at $6.1B (+36%)04:52 - Harvey Raises $150M at $8B Valuation (+multi-round 2025 surge)05:34 - OpenAI Revenue Soars … $574.9B Secondary Valuation (+15%)06:35 - OpenAI 1M Business Customers + 800M Weekly Users07:25 - OpenAI-AWS $38B Cloud Deal Reshapes Infra Market07:55 - Lambda + Microsoft Multibillion AI Infra Deal (+90.1%)08:56 - Gemini Prediction Markets Expand Crypto Derivatives Frontier09:57 - Perplexity v. Amazon Tests AI Agent Commerce Rules10:54 - Anthropic $70B revenue + wins Cognizant Deal12:19 - Epic Games-Google Settlement Redefines App-Store Economics13:15 - SpaceX Starlink 8M Users >> $446.3B Secondary Valuation (+11.6%)

DoorDash: Callers Explain WHY they use it after stock tanks | Mundo Clip 11-6-25See omnystudio.com/listener for privacy information.

Dan Nathan, Guy Adami & Liz Thomas break down the top market headlines and bring you stock market trade ideas for Thursday, November 6th. -- Learn more about FactSet: https://www.factset.com/lp/mrkt-callMRKT Call is brought to you by our presenting sponsors CME Group, FactSet, SoFi & MoneyLionSign up for our emailsFollow us on Twitter @MRKTCallFollow @GuyAdami on TwitterFollow @CarterBWorth on TwitterFollow us on Instagram @RiskReversalMediaLike us on Facebook @RiskReversalWatch all of our videos on YouTube Learn more about your ad choices. Visit megaphone.fm/adchoices